109 related articles for article (PubMed ID: 35723843)
1. A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Nomura M; Kii T; Kawada J; Hirota M; Ohta T; Matsuyama J; Sakai D; Shimokawa T; Kurokawa Y; Kawakami H; Tsujinaka T; Satoh T
Esophagus; 2022 Oct; 19(4):711-716. PubMed ID: 35723843
[TBL] [Abstract][Full Text] [Related]
2. Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.
Nomura M; Iwasa S; Tsushima T; Kato K; Yasui H; Boku N; Muto M; Muro K
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1209-1216. PubMed ID: 27778070
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Mori Y; Kikuchi O; Horimatsu T; Hara H; Hironaka S; Kojima T; Kato K; Tsushima T; Ishihara R; Mukai K; Uozumi R; Tada H; Kasai H; Kawaguchi A; Muto M
Esophagus; 2022 Jul; 19(3):444-451. PubMed ID: 35050435
[TBL] [Abstract][Full Text] [Related]
4. S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Ito T; Honma Y; Hirano H; Shoji H; Okita N; Iwasa S; Takashima A; Kato K; Boku N
Anticancer Res; 2019 Jul; 39(7):3931-3936. PubMed ID: 31262923
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
[TBL] [Abstract][Full Text] [Related]
9. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
Lee DH; Kim HR; Keam B; Kato K; Kuboki Y; Gao H; Yovine A; Robbins SH; Ahn MJ
Cancer Med; 2023 Aug; 12(15):16066-16075. PubMed ID: 37489066
[TBL] [Abstract][Full Text] [Related]
11. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
14. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).
Lee DK; Park SR; Kim YH; Lee YG; Shin SJ; Ahn BC; Lee SS; Lim SM; Kim HR; Cho BC; Hong MH
Oncoimmunology; 2024; 13(1):2371563. PubMed ID: 38919826
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Abraham P; Gricar J; Zhang Y; Shankaran V
Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
